Avalo Therapeutics CFO Christopher Ryan Sullivan disposes of common shares worth $1.44 millionPUBT·Aug 19 at 03:11 PMAVTX+1.56%
Avalo Therapeutics CMO Mittie Doyle disposes of 679 common shares worth $13,580PUBT·Aug 12 at 03:11 PMAVTX+1.56%
Avalo Q2 2026 Earnings: $472.2 Million Supports 2027 Clinical MilestonesTradingKey·Aug 6 at 07:00 AMAVTX+1.56%
Avalo Therapeutics posts corporate deck spotlighting IL-1β inhibitor pipeline for hidradenitis suppurativaPUBT·Aug 6 at 06:26 AMAVTX+1.56%
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business UpdatesUnusual Whales·Aug 6 at 06:04 AMAVTX+1.56%
DV Trading LLC Invests $5.38 Million in Avalo Therapeutics, Inc. $AVTXMarket Beat·Aug 2 at 03:24 AMAVTX+1.56%
Avalo Therapeutics CMO Mittie Doyle disposes of common shares worth $20,000PUBT·Jul 29 at 03:06 PMAVTX+1.56%
What Avalo Therapeutics (AVTX)'s Russell Index Additions and Board Refresh Mean for ShareholdersSimplywall·Jul 7 at 02:54 PMAVTX+1.56%
Avalo Therapeutics CMO Mittie Doyle disposes of 4,654 common shares valued at $93,080PUBT·Jul 2 at 03:07 PMAVTX+1.56%
